ライフサイエンスコーパス: trial

1 24-week treatment period (the phase 3 APeX-2 trial).

2 n patient outcomes for 26 first line therapy trials).

3 abel, parallel-group, randomized, controlled trial.

4 and that this is sustained during the entire trial.

5 atients (62%) were ineligible for the ZUMA-1 trial.

6 randomised, double-blind, placebo-controlled trial.

7 There was no masking in this open-label trial.

8 treatment in the context of a MERS clinical trial.

9 , stage III melanoma in the phase 3 COMBI-AD trial.

10 e preexposure prophylaxis initiative (iPrEx) trial.

11 tion (NACR) enrolled in a phase III clinical trial.

12 te-to-severe atopic dermatitis in a phase 2b trial.

13 s; 109 [72%] women), 115 (76%) completed the trial.

14 n-inferiority randomised controlled clinical trial.

15 state anxiety/instability were recorded per trial.

16 sults of the phase III, open-label KATHERINE trial.

17 earn about) only one of several cues on each trial.

18 time to task failure was observed in either trial.

19 ntracerebral Hemorrhage Evacuation Phase III trial.

20 SB and colonic ACE2 expression in 3 clinical trials.

21 evaluated in endocrine-resistant BC clinical trials.

22 vations and the results of previous clinical trials.

23 dvancing novel vaccine candidates into human trials.

24 -term fate requires assessment through field trials.

25 esearch questions and direct future clinical trials.

26 ed in randomized placebo-controlled clinical trials.

27 developed for use in international clinical trials.

28 essential to support initiation of clinical trials.

29 r the similar trials than for the dissimilar trials.

30 rrants confirmation in subsequent randomized trials.

31 ed in large-scale observational and clinical trials.

32 of protection that may guide future vaccine trials.

33 udies have applied this knowledge to vaccine trials.

34 is of stimulation sites from 14 clinical TMS trials.

35 s and an influence of past trials on current trials.

36 ta and an ideal endpoint for desensitization trials.

37 thoughtful design of rigorous presymptomatic trials.

38 migatinib, and all are currently in clinical trials.

39 s the evaluation of TMV-NPNAx5/ALFQ in human trials.

40 lp optimize and guide the design of clinical trials.

41 included studies were randomized controlled trials.

42 morbidities in comparison with earlier S-ICD trials.

43 urrently being evaluated in phase 1 clinical trials.

44 s use is supported by large clinical outcome trials.

45 is often difficult to achieve in prospective trials.

46 ings of the completed cardiovascular outcome trials.

47 emented in clinical research and therapeutic trials.

48 s requires testing in prospective randomised trials.

49 t subgroups from DAPA-HF and EMPEROR-Reduced trials.

50 rates for comparison with published clinical trials.

51 may be useful for other GA repurposing drug trials.

52 ants closest to MCI for secondary prevention trials.

53 Compared with the registrational ZUMA-1 trial, 129 patients (43%) in this SOC study would not ha

54 meta-analysis was conducted from randomized trials (2001-2020) that studied discontinuation of aspir

55 andomized, active-controlled, double-blinded trial, 444 adults 60 through 64 years of age were random

56 Twenty-nine cases were resolved via jury trial, 8 of which were associated with plaintiff verdict

57 In this randomized, controlled pilot trial, a post-debridement systemic antibiotic therapy co

58 in a systematically selected set of clinical trials (accuracy > 84% for predicting statistically sign

59 Few trials addressed prevention or cessation of tobacco prod

60 In this open-label, randomised controlled trial, adults (aged 16-55 years) with symptomatic primar

61 6) enrolled in 3 phase-3 randomized clinical trials (AMAGINE -1 [Efficacy, Safety, and Withdrawal and

62 tive attention interact during learning from trial and error across age groups.

63 Institute opted against an explanatory diet trial and for a pragmatic multiple risk-factor intervent

64 esolution of Intraventricular Hemorrhage III trial and the Minimally Invasive Surgery Plus Alteplase

65 n NIRF nanoprobes has translated to clinical trials and it will further translate to cancer managemen

66 to the limited activity of HDACi in clinical trials and offers direction for future approaches.

67 Randomized controlled trials and prospective observational studies evaluating

68 ness is consistent with efficacy in clinical trials and supports current recommendations that VMMC is

69 We identified three eligible trials and were able to obtain updated results for event

70 were molecularly eligible for entry into the trial, and 302 entered the trial to receive genotype-mat

71 nanodevices are currently tested in clinical trials, and none of them are approved by health agencies

72 t data from the Virtual International Stroke Trials Archive-ICH trials dataset, Clot Lysis: Evaluatin

73 Longer and larger trials are necessary to evaluate the efficacy and safety

74 Future clinical trials are needed to confirm these findings.

75 Ongoing trials are testing antiviral therapies, immune modulator

76 review' that distils the results of vaccine trials as they become available.

77 We did an open-label, randomised clinical trial at 57 centres in Brazil.

78 ed an observer-blinded randomized controlled trial at three university hospitals in Glasgow, United K

79 Arousal was modulated on a trial-by-trial basis using fear-conditioned (CS(+)) stimuli.

80 uld be confirmed in a prospective randomized trial before firm recommendations regarding clinical pra

81 During the subsequent unisensory trial, both trial-wise and cumulative exposure bias the

82 ave not been proven successful in randomized trials, but the quantity of early-life gluten exposure h

83 iffness magnitude decreased as a function of trials, but they changed at comparable rates in both env

84 Arousal was modulated on a trial-by-trial basis using fear-conditioned (CS(+)) stim

85 In the COAPT trial (Cardiovascular Outcomes Assessment of the MitraCl

86 European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209), publ

87 The other trial compared the effects of administering omalizumab v

88 d a 6-week, randomized, open-label crossover trial comparing amiloride/hydrochlorothiazide (5 mg/50 m

89 is a randomized, double-blind, multinational trial comparing monthly subcutaneous evolocumab 420 mg w

90 RT before 3 years of age in a prior clinical trial comparing nevirapine to lopinavir/ritonavir (Inter

91 Trials comparing original and generic PGAs did not show

92 ARTICIPANTS: Open-label, randomized clinical trial conducted at 17 UK hospitals.

93 of Health-funded, randomized, single-blinded trial conducted in 12 centers in the United States.

94 lticenter randomized double-blind sequential trial conducted in France, with interim analyses planned

95 In this randomized trial conducted in the public health care system of Braz

96 Our trial confirms the capability of LVAs to successfully re

97 used the CONsolidated Standards Of Reporting Trials (CONSORT) 2010 guideline, CONSORT for within-pers

98 Clinical perspective: Clinical trial data show that the efficacy of birch pollen AIT is

99 the COVID-19 'vaccine landscape', a clinical trials database and a 'living review' that distils the r

100 tual International Stroke Trials Archive-ICH trials dataset, Clot Lysis: Evaluating Accelerated Resol

101 nic Obstructive Pulmonary Disease Treatment) trial demonstrated a significant reduction in all-cause

102 Health in High Cardiovascular Risk Subjects) trial demonstrated that evolocumab added to a background

103 Several randomized trials demonstrated that chemoprophylaxis, or low-dose a

104 This trial design may be useful for other GA repurposing drug

105 Novel clinical trial designs offer potential solutions by attempting to

106 This trial did not identify a significant protective effect a

107 was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Si

108 multicentre, randomised, open-label, phase 3 trial done at 196 sites in 21 countries.

109 re-registered to the trial for a sequential trial drug.

110 The trial duration, the movement speed, the force impulse af

111 Background The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Gen

112 The trial enrolled 31 patients who received bendamustine on

113 ing tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patient

114 f tobacco products other than cigarettes; no trials evaluated effects of interventions on e-cigarette

115 Randomized, controlled trials evaluating the clinical efficacy of PCCs in patie

116 We present evidence that a clinical trial examining the effects of metformin on cognition an

117 (EXCEL Clinical Trial [EXCEL]; NCT01205776).

118 The trial findings were sensitive to the definition of myoca

119 erapy-including 14 that re-registered to the trial for a sequential trial drug.

120 ons for the conduct and analysis of clinical trials for cardiovascular disease and heart failure.

121 Future field trials for combinability and introgression may further o

122 Although the number of clinical trials for patients with COVID-19 is increasing, many ex

123 Although clinical trials for Stargardt are currently underway, the disease

124 evaluated in 4 years of second season field trials for the traits grain yield, number of ears, and g

125 eaningful conclusions at the end or during a trial, for many treatment strategies, simultaneously.

126 The ALLIANCE A041202 trial found that continuously administered ibrutinib in

127 and Cochrane Central Register of Controlled Trials from January 1, 1990, through July 1, 2019.

128 ED, SPORTDiscus, Web of Science and Clinical Trials.gov from their earliest records to January 2020.

129 AIDS Clinical Trials Group A5312 is a Phase 2A, open-label trial in wh

130 post-INSTI weight changes from AIDS Clinical Trials Group participants (A5001 and A5322).

131 Across experimental trials, growth rates differed among family lineages, and

132 Moreover, almost all trials have quantified treatment effects by using the ha

133 Phase III adjuvant trials have reported significant benefits in both relaps

134 tcome data from procalcitonin-guided therapy trials have shown similar mortality, but the essential q

135 Though several hundred clinical trials have tested immune-based approaches in childhood

136 for metastatic UM are limited, with clinical trials having little impact.

137 In clinical trials, HCV salvage treatment with Sofosbuvir/Velpatasvi

138 eptidomimetic inhibitor has entered clinical trial; however, small-molecule orally available antivira

139 L neurons could distinguish both valence and trial identity as well as or better than amygdala neuron

140 Acquired Immunodeficiency Syndrome Clinical Trials [IMPAACT] P1060); 183 age-matched, exposed but un

141 rospective cohort of an H pylori eradication trial in a Hispanic population.

142 collected as part of a randomised controlled trial in private for-profit dispensaries and health cent

143 econdary analyses of a randomized controlled trial in rural Malawi.

144 lity of (68)Ga-PSMA-HBED-CC in a test-retest trial in subjects with metastatic prostate adenocarcinom

145 Trials Group A5312 is a Phase 2A, open-label trial in which individuals with smear-positive pulmonary

146 ientists have initiated hundreds of clinical trials in an expedited effort to understand, prevent, an

147 vement errors decreased exponentially across trials in both learning tasks, optimal target selection

148 ICB) in melanoma and other cancers, clinical trials in breast cancer have reported low responses to t

149 ntly being evaluated in early phase clinical trials in children with high-risk MYCN-driven disease, w

150 ) RNA from subjects enrolled in the Clinical Trials in Organ Transplantation-09 study in which we ran

151 g with a periorbital shock (conditioning) or trials in which these stimuli were randomly presented in

152 NSAID use at baseline, NSAID use during the trial (incident NSAID use), and never users were describ

153 randomized, double-blind, placebo-controlled trial included patients with type 2 diabetes and urine a

154 Randomized controlled trials including the use of either agent alone are neede

155 er titer also risk-stratified candidates for trial inclusion.

156 g data from four large randomized controlled trials investigating different prevention strategies in

157 In this ongoing, double-blind, phase 1-3 trial involving nonhospitalized patients with Covid-19,

158 randomized, double-blind, placebo-controlled trial involving patients with atherosclerotic cardiovasc

159 At least 2 prospective clinical trials involving (177)Lu-PSMA agents are under way that

160 for long-term follow-up is ongoing, but the trial is closed to recruitment.

161 The trial is registered on ClinicalTrials.gov, NCT01654146 a

162 The trial is registered with ClinicalTrials.gov, NCT02004613

163 This trial is registered with ClinicalTrials.gov, NCT02842086

164 This trial is registered with ClinicalTrials.gov, NCT02924883

165 This trial is registered with ISRCTN, number 22944367.

166 s open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outc

167 lopment, testing and progression to clinical trials is overwhelmingly expensive.

168 , an anti-cancer agent in phase III clinical trials, kills cancer cells by destabilizing microtubules

169 resentation of women in HF guidelines and HF trial leadership need to be addressed.

170 Within PAD populations, data from trials may be difficult to interpret due to differences

171 Joint Global Health Trials (Medical Research Council, Department for Interna

172 ched Cochrane Central Register of Controlled Trials, MEDLINE, and Embase databases for randomized tri

173 s in which people incorporate their trial-to-trial memory uncertainty with potential rewards and prio

174 When adopted nationally outside the TIME trial, MIE was associated with an increase in total and

175 e years of data were used from two different trials, namely Regional Corn (Regional) and Optimum N ra

176 y in Patients With Acute Coronary Syndromes) trial (NCT02061891) evaluated the outcome of patients wi

177 The HIV Prevention Trials Network (HPTN) 067/Alternative Dosing to Augment

178 approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes and decr

179 , pragmatic, adaptive, randomised controlled trial of adding oseltamivir to usual care in patients ag

180 acebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of nicotine replacement therapy at 12 months (n =

181 = 66) participated in a randomized clinical trial of prolonged exposure therapy (n = 36) versus trea

182 th (NSIGHT2) study, a randomized, controlled trial of rapid diagnostic genomic sequencing of infants

183 Trial of roflumilast cream for chronic plaque psoriasis.

184 We conducted a double-blind trial of SER-287 in 58 adults with active mild-to-modera

185 We conducted a randomized clinical trial of text messaging (TM) versus no text messaging (N

186 In this platform trial of therapeutic agents, we randomly assigned hospit

187 In A Randomized trial of Unruptured Brain Arteriovenous malformations (A

188 aining sessions, mice received either paired trials of a tone coterminating with a periorbital shock

189 the horizon and the first data from clinical trials of autonomous RAS in urology are being published.

190 Randomized trials of BP pharmacologic treatment (more intensive BP

191 tion on likelihood of smoking cessation in 2 trials of bupropion at 26 weeks (n = 523; 17% [300 mg] a

192 ary outcomes, the use of ordinal outcomes in trials of cirrhosis decompensation may provide more powe

193 ndomized, placebo-controlled hormone therapy trials of conjugated equine estrogens (CEE) among posthy

194 M is optimal after spaced training, multiple trials of differential odor conditioning with rest inter

195 MEDLINE, and Embase databases for randomized trials of eHealth interventions in solid organ transplan

196 d of attention when reporting PROs in future trials of haematological malignancies.

197 Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 a

198 rates, equivalent to those seen in Phase III trials of other pangenotypic options, and has been condu

199 ant after excluding nonrandomized trials, or trials of poor quality (Jadad score <3).

200 leronlimab after blinded placebo-controlled trials of remdesivir, sarilumab, selinexor, or tocilizum

201 FDA approved opioids on the basis of pivotal trials of short or intermediate duration, often in narro

202 ntrols is justified in randomised controlled trials of surgical interventions provided there is a str

203 review, of which 12 were randomized clinical trials of therapy that included 3074 patients, 9 were ca

204 Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in

205 in tumor progression, results from clinical trials of various AKT inhibitors remain suboptimal, sugg

206 ivity and the task performance from trial to trial, offering a means of testing the causal relationsh

207 es of the triangles and an influence of past trials on current trials.

208 acts to FTC transmissions in the OptiLink HF trial (Optimization of Heart Failure Management Using Op

209 ("screen out") varied by various individual, trial, or site characteristics.

210 ed significant after excluding nonrandomized trials, or trials of poor quality (Jadad score <3).

211 rs that may be considered as future clinical trial outcomes.

212 n this parallel-group, double-blind clinical trial, participants were randomized to receive either 15

213 In this open-label, single-arm, phase 3 trial, participants were recruited from 24 academic site

214 In an open label clinical trials, participants with ASD were administered a single

215 re, double-blind, parallel-group, randomised trial, patients with advanced cancer, aged at least 18 y

216 motor learning where errors decrease across trials, people take into account their future, improved

217 Four registered randomized trials plan to evaluate ACEIs and ARBs for treatment of

218 clinical insights from the HAWK and HARRIER trials, postmarketing reports, and assessments from an i

219 The Myeloma XI trial protocol incorporated International Myeloma Workin

220 aims to improve the completeness of clinical trial protocol reporting by providing evidence-based rec

221 In an open-label, randomized controlled trial (RCT), consecutive patients with ACLF diagnosed wi

222 vity Trial (UPBEAT), a randomised controlled trial (RCT), of a lifestyle intervention (low glycaemic

223 rary were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs published from A

224 Several randomised controlled trials (RCTs) have assessed if induction of labour (IOL)

225 tematically identified randomized controlled trials (RCTs) investigating the safety and efficacy of s

226 enrolled double-blind, randomised controlled trials (RCTs).

227 practice and a large cost-saving in clinical trial recruitment.

228 The Netherlands Trial Register NTR-7307.

229 his study is registered with the EU Clinical Trials Register (EudraCT 2010-022134-89).

230 ions, lack of pre-specified protocols and/or trial registration, and poor reporting of adverse events

231 regulation of NK cells by Ebola glycoprotein.TRIAL REGISTRATIONClinicalTrials.gov NCT02313077.FUNDING

232 h the National Institutes of Health Clinical Trial registry, NCT02895269.

233 ary outcomes for phase II and phase III drug trials reported to the ClinicalTrials.gov registry.

234 on, and a new 3-item checklist to assess its trial reporting quality (TRQ), WPT-specific reporting qu

235 by loss of equipoise over the course of the trial, resulting in poor adherence to the assigned study

236 To shed light on the integrity of clinical trial results, this paper systematically analyzes the di

237 vent data and BCAR episodes from all six CTG trials revealed no safety concerns when compared with th

238 h risk of recurrent stroke, but two previous trials (SAMMPRIS and VISSIT) did not show superiority of

239 ualized risk estimates for better prevention trial selection.

240 There were four trial sites in hospitals in Ghana (Agogo, Tepa, Nkawie,

241 ty and methodological quality of split-mouth trials (SMTs) published during the past 2 decades and to

242 alyses using different estimates of clinical trial success rates, preclinical expenditures, and cost

243 loratory analysis of a randomized controlled trial support further investigation of IL-1beta inhibiti

244 Randomized clinical trials support the efficacy of MDMA in the treatment of

245 CVD events across latter-phase (II and III) trials supporting FDA approval of anticancer drugs from

246 measured fMRI activity for valid and invalid trials (target at cued/un-cued location, respectively),

247 rt negative results on a randomized clinical trial testing the combination of apremilast, a phosphodi

248 Accuracy was lower for the similar trials than for the dissimilar trials.

249 eview, we outline the landmark T1DM and T2DM trials that informed the current guidelines, we discuss

250 In preclinical trials, the recently developed tracer 2-methoxy-(18)F-DC

251 rent exploitation horizons (i.e., numbers of trials they might be asked to perform).

252 in which, after performing a initial set of trials, they selected a reward structure (ratio of point

253 is is a randomized and double-blind clinical trial to evaluate the efficacy of miltefosine combined w

254 enting the information from the physical the trial to help reduce its size and duration.

255 l, randomized, multicenter, two-arm phase II trial to investigate cisplatin and gemcitabine with or w

256 We performed a randomized, controlled trial to investigate the effects of a low FODMAP diet on

257 or entry into the trial, and 302 entered the trial to receive genotype-matched therapy-including 14 t

258 twork activity and the task performance from trial to trial, offering a means of testing the causal r

259 ns that can cause a nontrivial proportion of trials to assign more patients to an inferior arm, (4) d

260 ould be used for patient selection in future trials to determine if tricuspid valve intervention impr

261 syndrome (DS), translation to human clinical trials to improve cognition in individuals with DS has h

262 of the AI system paves the way for clinical trials to improve the accuracy and efficiency of breast

263 agnosis and management, and ongoing clinical trials to provide expanded treatment options.

264 by models in which people incorporate their trial-to-trial memory uncertainty with potential rewards

265 In the absence of controlled trials, treatment of neonatal seizures has changed minim

266 n enrolled in the Evolut Low Risk randomized trial underwent computed tomographic imaging 30 days and

267 he UK Pregnancies Better Eating and Activity Trial (UPBEAT), a randomised controlled trial (RCT), of

268 Ethanol for Untreated Persistent AF (VENUS) trial was an investigator-initiated, National Institutes

269 randomized, double-blind, placebo-controlled trial was conducted in infertility clinics in Tehran, Ir

270 However, neither trial was powered to assess effects on cardiovascular de

271 Trial was registered at DRKS (registration number: DRKS0

272 This trial was registered with the National Institutes of Hea

273 The trial was terminated prematurely because of slower-than-

274 ergoing anterior resection within the ROLARR trial was undertaken.

275 es delivered as part of a randomized control trial, WASH Benefits) in rural Bangladeshi household com

276 this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5-45 year-olds (N=148)

277 In this phase 1 and 2 trial, we administered HLA-mismatched anti-CD19 CAR-NK c

278 e "first-in-human" heart xenotransplantation trial, we propose a set of patient characteristics that

279 this single-arm, open-label, phase 2 basket trial, we recruited patients from 26 hospitals in six Eu

280 The coprimary outcomes of the trial were efficacy, as measured by the number of cases

281 Cryptococcal Meningitis Treatment for Africa trial were followed for 12 months.

282 Trials were eligible for inclusion if published between

283 Five trials were included; follow-up duration ranged from 12

284 The majority of the trials were performed in the setting of septic shock, an

285 data and safety monitoring board halted the trial when the numbers of clinical events were significa

286 Services) was a pragmatic cluster-randomized trial where the hospital was the unit of randomization.

287 recruitment process for the target clinical trial, which then can be used for augmenting the informa

288 The final analysis of the full trial will assess non-inferiority of the groups for the

289 emory mediate the aftereffect following both trial-wise and cumulative adaptation, but also show that

290 During the subsequent unisensory trial, both trial-wise and cumulative exposure bias the encoding of

291 non-linear mapping from value-differences to trial-wise drift rates.

292 We conducted a randomized trial with 40 children aged 4-15 years at the UCLA Child

293 vel, 2.1 mg/L), 12 633 (96.6%) completed the trial with ascertainment of primary end point status.

294 SCZ non-smokers into a double-blind clinical trial with four groups: placebo, 5 mg/d, 10 mg/d, and 20

295 There have been no multicountry field trials with liquefied petroleum gas (LPG) stoves, likely

296 safety or quality of life signals, a larger trial, with modifications to improve participation and c

297 .8-specific blockers have undergone clinical trials, with others in preclinical development, and the

298 verticular disease complications, leading to trial withdrawal.

299 recruited in a single-institution ancillary trial within the expanded-access program (NCT02475382) f

300 T) 2010 guideline, CONSORT for within-person trial (WPT) extension, and a new 3-item checklist to ass